Advanced Research and Development and Delivery of Adult and Pediatric Midazolam Autoinjectors That Have Received Emergency USE Authorization (EUA) or FDA Approval for the Treatment of Status Epilepticus Seizures in Adult and Pediatric Populations (2+
Contract Overview
Contract Amount: $104,152,986 ($104.2M)
Contractor: Crossject SA
Awarding Agency: Department of Health and Human Services
Start Date: 2022-06-22
End Date: 2027-06-21
Contract Duration: 1,825 days
Daily Burn Rate: $57.1K/day
Official Description: ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+